Analysts Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) PT at $9.95

Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) have earned a consensus recommendation of “Moderate Buy” from the ten research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $9.40.

A number of brokerages have weighed in on ALLO. Citizens Jmp upgraded shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 target price for the company in a research note on Friday. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 price objective on shares of Allogene Therapeutics in a research report on Friday. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $14.00 price objective on shares of Allogene Therapeutics in a research report on Friday.

Allogene Therapeutics Trading Up 2.6 %

Shares of ALLO opened at $1.94 on Friday. The firm has a market cap of $406.76 million, a PE ratio of -1.24 and a beta of 1.02. The firm has a fifty day simple moving average of $1.94 and a two-hundred day simple moving average of $2.31. Allogene Therapeutics has a 1-year low of $1.32 and a 1-year high of $4.74.

Allogene Therapeutics (NASDAQ:ALLO) last announced its earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06. As a group, research analysts forecast that Allogene Therapeutics will post -1.28 EPS for the current fiscal year.

Insider Buying and Selling

In other Allogene Therapeutics news, EVP Zachary Roberts sold 27,199 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $1.78, for a total value of $48,414.22. Following the sale, the executive vice president now owns 488,054 shares in the company, valued at $868,736.12. The trade was a 5.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Timothy L. Moore sold 14,746 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $1.71, for a total transaction of $25,215.66. Following the completion of the sale, the insider now owns 250,713 shares in the company, valued at approximately $428,719.23. The trade was a 5.55 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 52,710 shares of company stock valued at $92,125. Company insiders own 24.30% of the company’s stock.

Institutional Trading of Allogene Therapeutics

Several hedge funds have recently bought and sold shares of ALLO. Cibc World Markets Corp purchased a new stake in Allogene Therapeutics in the 4th quarter worth $26,000. PAX Financial Group LLC purchased a new stake in Allogene Therapeutics in the 4th quarter worth $27,000. RPO LLC purchased a new stake in Allogene Therapeutics in the 4th quarter worth $31,000. Caption Management LLC purchased a new stake in Allogene Therapeutics in the 4th quarter worth $32,000. Finally, Syon Capital LLC purchased a new stake in shares of Allogene Therapeutics during the 4th quarter valued at about $39,000. Hedge funds and other institutional investors own 83.63% of the company’s stock.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).